CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Polypodium leucotomosdrug
Likely dose
Polypodium leucotomos 7.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00520910
NCT00520910Phase 2Completed
CompareCT.gov

Single-Blind Study Determining the Efficacy of Polypodium Leucotomos Extract Supplement in Decreasing UVA Premutagenic and Photoaging Markers

University of Miami·interventional·Posted Aug 27, 2007·Updated Jun 18, 2019

In Brief

A Phase 2 clinical trial evaluating Polypodium leucotomos for Aging and Skin Abnormalities. Completed, enrolled 10 participants across 1 site.

Detailed Summary

With this study, the investigators will like to determine if taking a dose of the study medication, called Polypodium leucotomos (PL), prevents some of the changes in the skin caused by the adverse effects of UVA, a type of ultraviolet light.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAging, Skin Abnormalities
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 27, 2007
Enrollment StartAug 1, 2007
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.8 years ago

Interventions

Polypodium leucotomosdrug

Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.